EDESA BIOTECH, INC. Accounts Receivable, before Allowance for Credit Loss
EDESA BIOTECH, INC. (EDSA) had Accounts Receivable, before Allowance for Credit Loss of $700.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Balance Sheet › Assets
us-gaap:AccountsReceivableGross · last filed 2024-05-10
- 2024-03-31: Accounts Receivable, before Allowance for Credit Loss $700.00K.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |